Bayer and atara biotherapeutics enter strategic collaboration for mesothelin-targeted car t-cell therapies for solid tumors

Whippany, n.j. & south san francisco, calif.--(business wire)--bayer and atara biotherapeutics, inc. (nasdaq: atra) today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed car t-cell therapies for the treatment of solid tumors. the agreement includes the development candidate ata3271, an armored allogeneic t-cell immunotherapy, and an autologous version, ata2271, for high mesothelin-expressing tumors such as mali
ATRA Ratings Summary
ATRA Quant Ranking